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mental cost-effectiveness ratio (ICER). The analysis covered 10
years, with a Markov cycle of one day. Costs included medica-
tion, consultations and treatment interventions and additional
costs for attending special education. Quality-adjusted life years
(QALY) were used as effectiveness measures. Outcome proba-
bilities were taken from the medical literature and an expert
panel of ﬁve child psychiatrists and pediatricians. Univariate sen-
sitivity analyses were performed to assess the robustness of the
base case estimate. Multivariate sensitivity analysis was used to
estimate a worst and best case ICER. RESULTS: The incremen-
tal cost-effectiveness ratio of methylphenidate-OROS treatment
compared to IR-methylphenidate in youths with ADHD for
whom treatment with IR-methylphenidate is suboptimal, was
2004 euros per QALY. Total costs after 10 years were 15,739
euros for the IR-methylphenidate pathway and 16,015 euros for
the methylphenidate-OROS pathway. In the univariate sensitiv-
ity analysis, the ICER was sensitive to changes in resource use
and the probability of stopping stimulant treatment in favor of
IR-methylphenidate. An ICER of 0 was reached with a 6.2%
price reduction of methylphenidate-OROS. CONCLUSIONS:
Methylphenidate-OROS is a cost-effective treatment for youths
with ADHD for whom treatment with IR-methylphenidate is
suboptimal. With regard to the cost items evaluated in this analy-
sis, higher medication costs of methylphenidate-OROS were
compensated by savings on resource use, yielding similar 10-year
costs compared to treatment with IR-methylphenidate. Future
cost-effectiveness analyses should retrieve estimations for model
parameters from clinical trials or large databases and include
direct non-medical costs associated with methylphenidate 
treatment.
PMH18
DIRECT COST OF DEPRESSION—ANALYSIS OF A GERMAN
CLAIMS DATABASE
Gothe H1,Volmer T2, Höer A1, Mangiapane S1, Runge C2,
Glaeske G3, Häussler B1
1IGES GmbH, Berlin, Germany, 2Wyeth Pharma GmbH, Münster,
Germany, 3ZeS, Centre of Social Policy Research, Faculty 11: Human
and Health Sciences, University of Bremen, Germany, Bremen,
Germany
OBJECTIVES: To retrospectively evaluate 1-year direct health
care cost (antidepressants, hospital stays, rehabilitation) of
patients with depression based on claims data. METHODS:
Billing data of a German sickness fund with 4.7 million life years
insured were used for the period from 2001 to 2003. Beneﬁcia-
ries were included, if they were covered at least three months by
the health insurance and had either an inpatient or sick leave
diagnosis of depression (ICD 10: F32, F33) or at least two pre-
scriptions of an antidepressant (ATC: N06A*) during this
period. For each patient direct health care cost was derived from
the database for the individual observation period and stan-
dardized subsequently to obtain 1-year cost. RESULTS: Out of
1.54 million beneﬁciaries n = 75.078 fulﬁlled the inclusion cri-
teria (mean age: 48 ± 15 years; 57 % female). Total 1-year cost
of illness amounted to €363 per patient (SD: €1584) as actuar-
ial data. The median reimbursed cost of treating depression
accounted for €31, the maximum was €57,404 p.a. per patient,
representing that the majority of the patients caused relatively
low expenditures and only a small group generated high health
care cost. Stratiﬁcation of total cost shows that inpatient care
due to depression caused higher average cost per patient and year
(212 ± €1479) than antidepressant therapy administered by
ofﬁce-based physicians (93 ± €177) or rehabilitation (54 ± €389).
CONCLUSION: The study conﬁrms that hospitalization is the
main cost driver of depression. This is in line with current liter-
ature. There is also evidence that adequate antidepressant treat-
ment prevents from hospital stays. Though, the ﬁndings reveal a
distinct imbalance between inpatient and outpatient cost, espe-
cially for antidepressant pharmacotherapy. Keeping patients in
an ambulatory care setting, supported by an optimized pharma-
cotherapy, might contribute to reduced overall health care spend-
ing per patient.
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OBJECTIVES: It is suggested that full remission should be the
primary goal of depression treatment. However, few previous
studies have directly measured the impact of remission on eco-
nomic disease burden. The aims of this study were to compare
costs of patients in remission with patients not achieving remis-
sion after an episode of major depressive disorder (MDD) in a
Swedish primary care setting, and to determine effect of remis-
sion on overall cost of illness. METHODS: The cost of illness in
remitters and non-remitters was estimated based on of a natu-
ralistic longitudinal survey (HEADIS—Health Economic Aspects
of Depression in Sweden). Records from 447 patients with a
mean follow-up of 6 months were collected from 56 primary care
centre, and the resource use was analyzed for patients having at
least one follow-up visit. Unit costs were derived from standard
Sweden sources. Swedish prevalence estimates were applied to
per patient cost estimates to assess overall burden of illness
among remitters and non-remitters. RESULTS: Full remission
was achieved by 52% of the patients at end of follow-up. For
non-remitters and remitters, total annual per patient costs
amounted to SEK 128,000 and SEK 78,000, respectively. With
MDD prevalence of 5% and Swedish 2005 population exceed-
ing 9 million, overall burden of illness was SEK 46 billion.
Increasing the proportion of remitters by 10% would decrease
an overall burden of illness by 5%, to SEK 44 billion. CON-
CLUSIONS: Remission substantially affects economic burden of
depression, decreasing total per patient cost by almost 40%.
With high prevalence of MDD in Sweden, any strategy that will
increase the remission rate will also markedly reduce the overall
burden of illness. This indicates importance of full remission as
the primary goal of treatment of depression and strengthens evi-
dence that antidepressant treatments leading to rapid remission
may be most beneﬁcial.
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OBJECTIVES: The objective of this study was to estimate the
direct annual cost of treating patients with schizophrenia in
Greece, in 2005. METHODS: Due to the lack of quantitative
data, information on the treatment pathway and medical
resource utilization of patients were collected from a consensus
panel of 9 psychiatrists representing different medical settings
and geographic regions and 5 health economists. For estimating
costs a bottom up approach from the National Health System
perspective was used. Cost analysis included personnel salaries,
diagnostic procedures, medication, outpatient visits, hospitaliza-
tion and stay in supervised dwelling. Due to the variations
between hospital pricing and reimbursement, three-scenarios
were used to account for variability on hospitalization costs.
RESULTS: The panel of experts deﬁned three patient categories
based on the severity of the disease and the medical setting where
treatment is received: (a) outpatient setting (50% probability of
hospitalization for 20 days per year); (b) ambulatory care (100%
probability of hospitalization for 50 days per year); and (c) inpa-
tient setting (100% probability of hospitalization for 60 days per
year and 40% probability of 305-day stay in protected dwelling).
The annual direct cost of treatment per patient was found to be:
€3187 (€2659–€4166) in the ﬁrst category, €10,135 (€7429–
€13,972) in the second category and €20,782 (€17,482–€25,462)
in the third category. The total cost of treatment increased with
the severity of the disease and the use of hospitalization, while
the contribution of medication to the total cost decreased com-
pared to other cost attributes. CONCLUSIONS: The provision
of health care to schizophrenic patients has a high cost for the
health care system. Systematic data collection on medical
resource utilization must be established at the national level to
facilitate further research and guide the efﬁcient use of resources.
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OBJECTIVES: This analysis estimated the cost-utility of second-
line treatment for major depressive disorder using generic selec-
tive serotonin reuptake inhibitors (SSRIs), escitalopram,
paroxetine CR, sertraline or venlafaxine XR. METHODS: A
Markov probabilistic decision analysis was constructed with
cycle dependent transition probabilities for persistency over 52
weeks, examining whether persistent patients would have a
response, and if this response was followed by remission.
Response was °Y´50% improvement from baseline in depression
rating score. Remission was deﬁned as °Ü7 HAM-D or °Ü10
MADRS. Remission and response rates were obtained from pub-
lished clinical trials and entered into the model using beta dis-
tributions. Utilities were based on duration of treatment and
changed weekly over the year. Baseline utility scores were 0.35,
0.21, and 0.30 for remission, response, and treatment failure,
respectively; between days 56–365 utility scores were 0.85, 0.72,
and 0.58, respectively. Wholesale acquisition costs were used for
medication costs. Remission, response, and treatment failure
costs were obtained from the literature and were estimated using
gamma distributions. The analysis was conducted using 10,000
Monte Carlo simulations with ﬁrst- and second-order sampling
procedures. RESULTS: The lowest cost option was generic SSRI
agents ($3283), with the highest being venlafaxine XR ($4111).
The effectiveness was greatest for venlafaxine XR (35.2 quality-
adjusted life weeks (QALWs), followed by escitalopram (34.1),
sertraline (34.1), generic SSRIs (33.8), and paroxetine CR (33.4).
Cost per QALW ranged from $97 for generic SSRIs to $117 for
venlafaxine XR. The incremental cost effectiveness ratio (ICER)
for venlafaxine XR relative to generic SSRIs was $609. When
QALW are converted to quality-adjusted life years (QALYs), the
ICER per QALY for venlafaxine XR relative to generic SSRIs
was $31,621. CONCLUSIONS: Using a Monte Carlo Markov
model, the analysis suggests that venlafaxine XR is more effec-
tive in terms of QALWs and has an acceptable ICER relative to
generic SSRIs.
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The major cost to the health care system in treating schizophre-
nia is hospital based care. To help estimate the cost of treating
schizophrenia and to assess the effectiveness of treatment com-
prehensive data on rehospitalization rates are appropriate.
OBJECTIVE: To conduct a systematic review of the literature on
rehospitalization rates for schizophrenia. METHODS: Published
clinical trials of antipsychotic medications and large representa-
tive naturalistic studies were systematically identiﬁed by con-
ducting searches of the Cochrane Library Schizophrenia Group’s
Register and MEDLINE databases. Identiﬁed sources were sup-
plemented with a reference search for additional relevant litera-
ture. Studies were included if they were published from
1990–2004 and reported 1-year rehospitalization rates among
patients not hospitalized. This included (a) clinical trials of out-
patients or of recent discharge patients; and (b) naturalistic
cohorts followed after discharge from hospital. Hospitalization
rates were adjusted based on the sample size. Studies were strat-
iﬁed based on the patient group treated. RESULTS: Patients after
their ﬁrst hospitalization for schizophrenia (ﬁrst episode patients;
n = 36,192) from case registries in 5 nations had an average
annual readmission rate of 33% (range 15–55%). Of stable
response patients, comparison between patients on ﬁrst genera-
tion (conventional; n = 265) and second generation (novel; n =
628) antipsychotic regimes indicated that those on second gen-
eration were signiﬁcantly less likely to be readmitted (Mean dif-
ference = 3.02; 95% CI = 1.75:4.29). Similarly, of patients
treated for clinical exacerbation comparison between patients on
ﬁrst (n = 761) and second generation (n = 1141) regimes indi-
cated that those on a second generation regime were signiﬁcantly
less likely to be readmitted (Mean difference = 5.07; 95% CI =
4.41:5.72). CONCLUSIONS: Rehospitalization rates were sig-
niﬁcantly lower for patients on second than ﬁrst generation
antipsychotics. This ﬁnding appears to be robust across patient
groupings. The use of second generation antipsychotics may
reduce the cost of care.
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Violent crimes perpetrated by the mentally ill are a global
problem causing signiﬁcant ﬁnancial and human burden. Severe
mental disorders are associated with an increased risk of violent
offending. However, predicting violent offending in the mentally
